Compare Amer Sports Inc (AS) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amer Sports Inc vs Mesoblast Limited — how do they compare? Amer Sports Inc trades at $33.32 (market cap $19.69B), while Mesoblast Limited trades at $16.96 (market cap $2.21B). The key difference: Amer Sports Inc is far larger — about 8.9× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Amer Sports Inc nearer its low. Which is the better fit depends on your goals.
| AS | MESO | |
|---|---|---|
Market Cap | $19.69B | $2.21B |
Sector | Technology | Technology |
52-Week High | $41.96 | $20.96 |
52-Week Low | $29.54 | $12.88 |
Enterprise Value | $20.01B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amer Sports (AS) trades at $33.67, down 6.91% over 24 hours, with a bearish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.38 and revenue growth of 32% year-over-year, and raised full-year guidance. Key financials show a net income margin of 6.5% and positive cash flow from operations of $729.8 million in 2025.
The outlook is supported by analyst consensus with 12 buy ratings and a $58.67 price target, but risks include high valuation multiples like a P/E of 42.3 and competitive pressures in the sports apparel sector. Near-term focus is on Q2 2026 earnings due August 18, 2026, which could drive volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amer Sports Inc
Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, and Atomic. It designs and manufactures high-quality equipment, apparel, and footwear for athletes worldwide.
Read more on AS →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
